Cardiac Safety Network
The Cardiac Safety Network integrates preclinical and clinical cardiac safety analysis services from Spacelabs Healthcare, iCardiac Technologies and Charles River Laboratories. The Cardiac Safety Network will offer drug developers a complete solution with services that span from recruitment and monitoring of clinical trial subjects to the submission of cardiac safety data to the FDA.
For press release, click here.
______________________________________________________________________
Pfizer: iCardiac Technologies Enters into Non-Exclusive Cardiac Safety Alliance with Pfizer
In 2006, iCardiac Technologies entered into a multi-year research alliance with Pfizer Inc. to develop and validate advanced ECG-based cardiac safety biomarkers utilizing iCardiac’s COMPAS technology platform. The aim of the research alliance is the creation and implementation of new biomarkers, for use in clinical trials, that will enable pharmaceutical companies to better assess the cardiac safety profiles of their in-development and on-market drugs. The alliance includes a cross-licensing arrangement by which iCardiac has received rights to ECG analysis technologies developed within Pfizer for integration within iCardiac’s technology offering to the industry.
For press release, click here.
For press coverage, click here.
______________________________________________________________________
University of Rochester: The Heart Research Follow-up Program
The core technology of iCardiac was originally developed based on research conducted at the Heart Research Follow Up Program (HRFUP), a part of the University of Rochester Medical Center. iCardiac holds an exclusive license for the core technology and maintains a close collaborative relationship with HRFUP.
HRFUP, which is funded in part by National Institutes of Health grants, is a national and international leader in the science of heart arrhythmias and a rare genetic condition associated with an abnormal QT interval, called the congenital Long QTSyndrome (LQTS). HRFUP has been conducting research in the area of heart arrhythmias for nearly 30 years and maintains a staff of over 40 researchers. As a key academic research and clinical resource, the university keeps an International Registry for LQTS, and follows thousands of families who have this inherited condition. One of the
genetic forms of the QT prolongation syndrome is highly similar to the drug-induced syndrome, and the university's work focuses on developing the tools to identify individuals with either form. The HRFUP, under the direction of Dr. Arthur J. Moss and Dr. Wojciech Zareba, has extensive experience in the design, conduct, and analysis of world-wide, multicenter, clinical research studies ranging from 100-3,500 subjects.
